TY - JOUR
T1 - Telomerase activity in human renal cell carcinoma
AU - Mehle, Christer
AU - Piatyszek, Mieczyslaw A.
AU - Ljungberg, Börje
AU - Shay, Jerry W.
AU - Roos, Göran
N1 - Funding Information:
The authors thank Abby Cuttriss from the Office of International Scientific Visibility at Universit? C?te d'Azur for proof reading. This work has been funded by the Association de Recherche contre le Cancer (ARC), the Ligue D?partementale 06 de Lutte contre le Cancer, the Conseil D?partemental 06, the Canc?rop?le PACA, the French Government (National Research Agency, ANR-11-LABX-0028-01). CAP and KP received support from CANCER-ID, an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115749, resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies? in-kind contributions; and the European Liquid Biopsies Academy (ELBA) Innovative Training Networks (ITN) Horizon 2020 project H2020-MSCA-ITN-2017 (Towards widespread clinical application of blood-based diagnostic tools). Association de Recherche contre le Cancer, ARC, Ligue D?partementale 06 de Lutte contre le Cancer, Conseil D?partemental 06, Canc?rop?le PACA, French Government, National Research AgencyANR-11-LABX-0028-01115749, European Union's Seventh Framework Program, European Liquid Biopsies Academy, ELBA, Innovative Training Networks (ITN) Horizon 2020 projectH2020-MSCA-ITN-2017, CAP and KP have received in-kind contributions of the EFPIA partners of the EU/IMI consortium CANCER-ID. PH and SH have declared no conflict of interest.
Funding Information:
This work has been funded by the Association de Recherche contre le Cancer (ARC), the Ligue Départementale 06 de Lutte contre le Cancer, the Conseil Départemental 06, the Cancéropôle PACA, the French Government (National Research Agency, ANR-11-LABX-0028-01). CAP and KP received support from CANCER-ID, an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115749, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in-kind contributions; and the European Liquid Biopsies Academy (ELBA) Innovative Training Networks (ITN) Horizon 2020 project H2020-MSCA-ITN-2017 (Towards widespread clinical application of blood-based diagnostic tools).
PY - 1996
Y1 - 1996
N2 - Telomeres have a vital role in maintaining chromosome stability and are essential for long term viability. Since the very ends of linear chromosomes cannot replicate, telomeres shorten in normal somatic cells eventually resulting in growth inhibition. However, most immortal cell lines maintain stable telomeres indicating that mechanisms exist to compensate for the end replication problem. Telomerase activity, leading to synthesis of telomeric DNA repeats, has been proposed to be an important step in the immortalization process of tumor cells. In the present study, 56 renal cell carcinomas were tested for telomerase activity using the sensitive TRAP (telomeric repeat amplification protocol). Forty of the analysed tumors (71%) were positive for telomerase activity, whereas none of the 56 corresponding normal kidney samples showed telomerase activity. All telomerase negative tumors had a reduction in mean telomere restriction fragment (TRF) length and a decrease in total telomere repeat hybridization signal, though cases were observed with an increase in peak TRF lengths. No obvious association between the presence of telomerase activity and clinicopathological parameters (histopathologic grade, DNA-ploidy, stage and clinical outcome) was found. The high frequency of detection of telomerase activity in the renal cell carcinomas indicates that this enzyme is likely to be an important factor involved in the evolution of this tumor type.
AB - Telomeres have a vital role in maintaining chromosome stability and are essential for long term viability. Since the very ends of linear chromosomes cannot replicate, telomeres shorten in normal somatic cells eventually resulting in growth inhibition. However, most immortal cell lines maintain stable telomeres indicating that mechanisms exist to compensate for the end replication problem. Telomerase activity, leading to synthesis of telomeric DNA repeats, has been proposed to be an important step in the immortalization process of tumor cells. In the present study, 56 renal cell carcinomas were tested for telomerase activity using the sensitive TRAP (telomeric repeat amplification protocol). Forty of the analysed tumors (71%) were positive for telomerase activity, whereas none of the 56 corresponding normal kidney samples showed telomerase activity. All telomerase negative tumors had a reduction in mean telomere restriction fragment (TRF) length and a decrease in total telomere repeat hybridization signal, though cases were observed with an increase in peak TRF lengths. No obvious association between the presence of telomerase activity and clinicopathological parameters (histopathologic grade, DNA-ploidy, stage and clinical outcome) was found. The high frequency of detection of telomerase activity in the renal cell carcinomas indicates that this enzyme is likely to be an important factor involved in the evolution of this tumor type.
KW - Clinical course
KW - Renal cell carcinoma
KW - Telomerase
UR - http://www.scopus.com/inward/record.url?scp=0029890015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029890015&partnerID=8YFLogxK
M3 - Article
C2 - 8700542
AN - SCOPUS:0029890015
SN - 0950-9232
VL - 13
SP - 161
EP - 166
JO - Oncogene
JF - Oncogene
IS - 1
ER -